Results 191 to 200 of about 7,402 (232)

Measles virus: Background and oncolytic virotherapy

, 2018
Sankhajit Bhattacharjee, Pramod Kumar Yadava   +1 more
openalex   +1 more source

Oncolytic virotherapy augments self-maintaining natural killer cell line cytotoxicity against neuroblastoma. [PDF]

Cancer Immunol Immunother
Quinn CH, Julson JR, Markert HR, Nazam N, Butey S, Stewart JE, Coleman JC, Markert JM, Leavenworth JW, Beierle EA.   +9 more
europepmc   +1 more source

Autophagy-based therapy for hepatocellular carcinoma: from standard treatments to combination therapy, oncolytic virotherapy, and targeted nanomedicines. [PDF]

Clin Exp Med
Rahdan F, Abedi F, Dianat-Moghadam H, Sani MZ, Taghizadeh M, Alizadeh E.   +5 more
europepmc   +1 more source

Analysis of a Multiple Delays Model for Treatment of Cancer with Oncolytic Virotherapy

, 2019
Adil El Alami Laaroussi, Mohamed El Hia, Mostafa Rachik, Rachid Ghazzali   +3 more
openalex   +1 more source

Combination of Oncolytic Virotherapy with Different Antitumor Approaches against Glioblastoma. [PDF]

Int J Mol Sci
Ageenko A, Vasileva N, Richter V, Kuligina E.   +3 more
europepmc   +1 more source

Anti-viral Immunity in the Tumor Microenvironment: Implications for the Rational Design of Herpes Simplex Virus Type 1 Oncolytic Virotherapy

, 2019
Paul J. F. Rider, Ifeanyi K. Uche, Larissa Sweeny, Konstantin G. Kousoulas   +3 more
openalex   +2 more sources

p53-armed oncolytic virotherapy induces abscopal effect in osteosarcoma by promoting immunogenic cell death. [PDF]

Mol Ther Oncol
Demiya K, Tazawa H, Kondo H, Kure M, Mochizuki Y, Komatsubara T, Yoshida A, Uotani K, Hasei J, Fujiwara T, Kunisada T, Urata Y, Kagawa S, Ozaki T, Fujiwara T.   +14 more
europepmc   +1 more source

Microbubble-Protected Oncolytic Virotherapy Targeted by Sonoporation Induces Tumor Necrosis and T-Lymphocyte Infiltration in Humanized Mice Bearing Triple-Negative Breast Cancer. [PDF]

Int J Mol Sci
Sitta J, De Carlo F, Kirven I, Tackett JH, Penfornis P, Dobbins GC, Barbier M, Del Valle L, Larsen CT, Schutt EG, Li R, Howard CM, Claudio PP.   +12 more
europepmc   +1 more source

Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma [Corrigendum]

, 2019
Hani M. Babiker, Irbaz Bin Riaz, Muhammad Husnain, Mitesh J. Borad   +3 more
openalex   +2 more sources

Octyl itaconate enhances VSVΔ51 oncolytic virotherapy by multitarget inhibition of antiviral and inflammatory pathways. [PDF]

Nat Commun
Kurmasheva N, Said A, Wong B, Kinderman P, Han X, Rahimic AHF, Kress A, Carter-Timofte ME, Holm E, van der Horst D, Kollmann CF, Liu Z, Wang C, Hoang HD, Kovalenko E, Chrysopoulou M, Twayana KS, Ottosen RN, Svenningsen EB, Begnini F, Kiib AE, Kromm FEH, Weiss HJ, Di Carlo D, Muscolini M, Higgins M, van der Heijden M, Arulanandam R, Bardoul A, Tong T, Tong T, Ozsvar A, Hou WH, Schack VR, Holm CK, Zheng Y, Ruzek M, Kalucka J, de la Vega L, Elgaher WAM, Korshoej AR, Lin R, Hiscott J, Poulsen TB, O'Neill LA, Roy DG, Rinschen MM, van Montfoort N, Diallo JS, Farin HF, Alain T, Olagnier D.   +51 more
europepmc   +1 more source